B
iliary atresia (BA) is an obstructive neonatal cholangiopathy of unknown cause. Even with Kasai hepatoportoenterostomy to relieve extrahepatic obstruction, approximately half of infants require liver transplantation by 2 years of age, whereas the remaining infants who survive with native liver (SNL) are at substantial risk for sequelae of chronic cholestatic liver disease, portal hypertension, and progression to liver transplantation. [1] [2] [3] There is limited information regarding the subsequent clinical course in BA SNL children who do not require early liver transplantation by age 2.
A major impediment to stratifying or predicting the progression of portal hypertension in BA SNL children after age 2 involves a lack of knowledge of markers that correlate with disease progression. In this report, we evaluate g-glutamyltransferase (GGT) at age 2 as a potential biomarker for the subsequent development of thrombocytopenia, a recognized surrogate indicator for disease progression and portal hypertension in BA. 4 These results suggest that this readily obtainable laboratory test may be a clinical indicator of disease progression in BA SNL subjects.
Methods
A retrospective review was completed for BA SNL subjects cared for at 3 large North American pediatric liver centers (Children's Healthcare of Atlanta, Atlanta, GA; Texas Children's Hospital, Houston, TX; and The Hospital for Sick Children, Toronto, Canada). Eligible subjects were born between 1997 and 2010, diagnosed with BA SNL at age 2, and followed until at least 4 years of age. A total of 46 children met criteria.
Variables collected for analysis included age, gender, race, as well as GGT and platelet levels at 2, 4, 5, and 6 years of age. Classification and regression trees analysis determined that a GGT level of 109 U/L at age 2 correlated with thrombocytopenia (platelet count <150 Â 10 3 /mL) at age 6. Using a practical cut point GGT level of 100 U/L for subsequent analyses, we evaluated the association between GGT levels < or !100 U/L at age 2 with platelet counts at 4, 5, and 6 years of age (controlling for race, gender, and study location) using generalized linear mixed models. To estimate the linear relationship between 1 time point for GGT and platelet levels, linear regression models were used. Comparison of median platelet levels of the 2 groups was conducting using Wilcoxon rank sum tests. Sensitivity and specificity analysis was performed on the final models. P values < .05 were considered significant in all analyses.
Results
Regression model analysis indicated that a GGT !100 U/L at 2 years of age had a predictive positive relationship with thrombocytopenia at 4, 5, and 6 years of age. BA subjects with a GGT !100 U/L at age 2 had a statistically significant lower median platelet level (160 Â 10 3 /mL vs 211 Â 10 3 /mL), which continued to significantly decline at 4, 5, and 6 years of age. In comparison, subjects with a GGT <100 U/L had essentially stable platelet counts over the next 4 years. This discrepancy between the 2 groups widened with each subsequent year (Figure 1) . A GGT !100 U/L at 2 years of age predicted thrombocytopenia at 4 (sensitivity, 0.88; specificity, 0.57), 5 (sensitivity, 0.89; specificity, 0.64), and 6 years of age (sensitivity, 0.94; specificity, 0.61), whereas a GGT <100 U/L at age 2 predicted a low risk of developing subsequent thrombocytopenia (negative predictive value of 0.89, 0.92, and 0.93 at 4, 5, and 6 years, respectively).
Discussion
These data indicate an apparent stratification of BA SNL subjects for the development of thrombocytopenia in early childhood based on a serum GGT level above or below 100 U/L at age 2. When stratified by this GGT level at age 2, there was a clear distinction not only in initial platelet counts, but in the progression of thrombocytopenia, seen only in those with a GGT !100 U/L at age 2. Thus, serum GGT levels obtained at age 2 may predict the development of a cardinal feature of portal hypertension, thrombocytopenia, in BA SNL patients who previously were considered to have a "successful" Kasai hepatoportoenterostomy.
This study links serum GGT levels at age 2 to future platelet counts, perhaps as a surrogate for the development of portal hypertension and its clinical consequences. [5] [6] [7] [8] Because the sequelae of portal hypertension in BA SNL often occurs slowly, 9 larger long-term studies are needed to identify if GGT levels at age 2 predict sentinel clinical events during childhood, adolescence, and young adulthood. Finally, if validated, GGT levels may ultimately participate in modeling the natural history, and evaluating the response to therapeutic interventions, in BA SNL patients. Figure 1 . Stratification of platelet levels by serum GGT levels < or !100 U/L at age 2. At ages 2, 4, 5, and 6, box and whisker plots (black bar represents median, box extends 25th-75th percentiles, and whiskers 5th-95th percentiles) relating platelet levels at the indicated ages. (Left) Those with serum GGT levels <100 U/L at age 2. (Right) Serum GGT levels !100 U/L at age 2. n, subject numbers at each age group. Paired comparison P values noted above the plot (within group [braces] and between groups [boxed] P values). The defining level for thrombocytopenia, 150,000/mL, is delineated by the texted block arrow and interrupted dashed gray horizontal line. NS, not significant.
